We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
TheraVet SA | EU:ALVET | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.022 | -3.12% | 0.684 | 0.64 | 0.684 | 0.71 | 0.68 | 0.71 | 1,969 | 16:40:00 |
Regulatory News:
TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the recruitment of Brakke Consulting to help strategize Company growth on the US market. Brakke – www.brakkeconsulting.com - is one of the leading consulting firms in the veterinary market with a solid track record of upscaling vet companies on the US market.
TheraVet has been commercializing BIOCERA-VET® for almost a year now in the US market, the largest market in animal health. Since its US market entry, the Company has been focused on launching the 9 presentations of its BIOCERA-VET® line; BIOCERA-VET® COMBO-CLEAN being the latest one launched in October 2023. To that aim, the Company has initiated a two-pilar plan: (i) the process, development, and delivery of direct sales to customers and (ii) the development of the company network and products awareness with participation in conferences, talks, clinical studies and reach to Key Opinion Leaders.
The Company’s next objectives are to rapidly grow from its existing base, expand its presence and to be recognized as a major player in the US orthopedics market. TheraVet has retained Brakke Consulting to help meet its objective based on a 3-step plan (structured with go/no go decision points):
This plan will be designed and implemented with the assistance of Brakke Consulting, the premier consulting firm serving the animal health, animal nutrition and veterinary industries on the US market. Its consultants are seasoned industry professionals with strong credentials in leadership, management, finance, sales, distribution, marketing, brand development, communications, and market research.
About TheraVet SA TheraVet is a veterinary biotechnology company specializing in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, has its head office in Belgium (Gosselies) with a US subsidiary.
Webshop and more information at bioceravet.com For more information about the company, visit the TheraVet website Follow us on LinkedIn / Facebook / Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20240219012268/en/
TheraVet Chief Operating Officer Sabrina Ena investors@thera.vet Tel: +32 (0) 71 96 00 43
NewCap Investor Relations and Financial Communications Théo Martin / Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44 71 94 94
Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33 (0)1 44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort lemonfort@newcap.fr Tel: + 32 (0) 489 57 76 52
1 Year TheraVet Chart |
1 Month TheraVet Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions